Tohoku Innovation Capital

Future Ink Corporation, founded in 2016 and based in Yonezawa, Japan, specializes in the development, manufacturing, and marketing of printed electronics and related products. The company produces innovative printable film sensors that can be seamlessly integrated into various designs, offering practical solutions to everyday challenges. Future Ink focuses on creating sensor devices that facilitate communication and enhance the well-being of vulnerable populations, including the elderly, individuals with disabilities, and infants. By providing valuable information about users' health and environment, these devices aim to alleviate the invisible stresses of modern life and help users regain their vitality. In addition to its core manufacturing and sales activities, Future Ink engages in the design, prototyping, and development of medical equipment, while also assessing the performance of electronic devices and materials through its consignment services.

Human Metabolome Technologies, Inc. is a biotechnology company based in Tsuruoka, Japan, specializing in metabolomics technologies and solutions aimed at drug discovery, diagnosis, and food production. Established in 2003, the company offers a range of metabolome analysis services, including global profiling, targeted assays, flux analysis, and lipidomics. It is actively involved in developing biomarkers, such as Phosphorylethanolamine, which serves as a marker for major depressive disorder. The company's solutions also span areas like cancer metabolism, metabolic flux analysis, preclinical and clinical research, food and nutrition, and microbiome applications. Human Metabolome Technologies collaborates with institutions such as the Institute for Advanced Biosciences and Keio University to enhance its metabolome analysis technology, positioning itself as a key player in the biotechnology sector.